How effective is stem cell therapy for spinal cord injury?

In the CELLTOP trial from Mayo Clinic, published in Nature Communications in 2024, adults with traumatic SCI who received MSCs into the spinal fluid had no serious treatment-related adverse events, and several showed improvements in sensory and motor function. At Stem Cell Mexico, SCI protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, usually by intravenous (IV) infusion and, in selected cases, by an additional intrathecal application. Effectiveness depends on the level and completeness of the injury, the time since it occurred and, above all, on rehabilitation. Results vary between patients, and they are best measured with the same tests your therapists use.

This guide explains how effectiveness is measured in SCI, what research shows, which factors influence results and what improvement can look like in daily life.

How effectiveness is measured in SCI

Because SCI affects many body functions, several standardized tools are used:

• ISNCSCI examination: the international standard exam that scores motor strength in key muscles and sensation (light touch and pinprick) on each side of the body, and determines the ASIA Impairment Scale (AIS) grade.
• AIS grade: from A (complete) to E (normal). A change of one grade is significant, but smaller changes in motor or sensory scores can also be meaningful.
• SCIM (Spinal Cord Independence Measure): evaluates self-care, breathing, bladder and bowel management and mobility.
• Walking measures for people with incomplete injuries, such as the WISCI index or timed walking tests.
• Spasticity, pain and bladder questionnaires.
• Quality-of-life measures.

For individual patients, the most meaningful outcomes are often specific: holding a cup, transferring with less help, sitting balance, less spasticity at night or better bladder awareness.

What research shows

CELLTOP trial (Mayo Clinic, 2024)

Ten adults with traumatic SCI received a single dose of MSCs by intrathecal injection. The primary safety endpoint was met, with no serious adverse events attributed to the treatment. Headache and musculoskeletal pain were common and managed with simple medications. Several participants showed improvements in sensory and motor scores during follow-up.

Regulatory experience in Japan

In 2018, Japan granted conditional, time-limited approval to an MSC product for SCI, based on clinical data showing neurological improvement in treated patients.

Systematic reviews

Reviews of human MSC studies in SCI report a good safety profile and improvements in sensory and motor scores, as well as in independence measures, in some patients, particularly when cells are combined with rehabilitation.

Safety of umbilical cord MSCs

A 2026 meta-analysis of IV umbilical-cord-derived MSCs in Stem Cells Translational Medicine found temporary fever as the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled trials.

How MSCs may help

MSCs from Wharton's jelly release anti-inflammatory, neuroprotective and trophic factors that may reduce inflammation around the injury, protect surviving nerve fibers and myelin, support blood vessel formation and create a more favorable environment for repair and neuroplasticity. The IV route distributes these signals through the body, and the intrathecal route places cells in the spinal fluid, closer to the injured cord.

Factors that influence effectiveness

• Completeness of injury: incomplete injuries (AIS B, C or D) have more surviving connections and more potential for measurable change than complete injuries (AIS A).
• Level of injury: cervical, thoracic and lumbar injuries affect different functions and goals.
• Time since injury: the subacute phase offers more natural plasticity; in the chronic phase, goals focus on specific functional gains.
• Rehabilitation intensity: consistent, activity-based therapy is one of the strongest predictors of progress.
• General health: skin integrity, bladder management, nutrition, sleep and infections affect recovery.
• Age and other conditions, such as diabetes or heart disease, which affect healing and endurance.

What improvement can look like

When changes occur, they are usually gradual and specific. Examples include:

• New or improved sensation below the injury.
• Small gains in muscle activation, such as finger or trunk movements.
• Better sitting balance and easier transfers.
• Reduced spasticity or nerve pain.
• Better bladder or bowel awareness.
• More energy and endurance during therapy.

For some patients these changes are meaningful; others notice modest change. Measuring before and after treatment with your therapists is the clearest way to see your own result.

A typical timeline

• First days: headache or back discomfort after an intrathecal application, or temporary fever after IV infusion, can occur.
• Weeks to months: some patients notice changes in sensation, spasticity or energy.
• Three, six and twelve months: recommended times to repeat the ISNCSCI exam, SCIM and functional measures with your rehabilitation team.

What our patients usually receive

Based on the treatment plans our team prepares for neurological patients, a typical SCI protocol at Stem Cell Mexico includes:

• Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on body weight and medical review.
• An additional intrathecal application (similar to an epidural, usually about 60 million cells) in selected cases, after the doctor reviews your medical reports and confirms you are a candidate.
• One night at our facilities, sometimes two, with nursing and medical monitoring, including support for transfers, bladder and bowel care and pressure-injury prevention.
• Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and wheelchair-accessible transportation from the San Diego airport area.

SCI plans typically cost $7,000 to $9,500 USD. Our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Safety considerations specific to SCI

• Autonomic dysreflexia: in injuries at or above the sixth thoracic level, a sudden rise in blood pressure can be triggered by a full bladder, constipation or skin pressure. Staff are trained to recognize and manage it.
• Pressure injuries: regular repositioning and pressure-relieving surfaces protect the skin during travel and the stay.
• Temperature control: people with high injuries may have difficulty regulating temperature, so fever is monitored closely.
• Urinary infections: any active infection is treated before the application.

Questions families often ask

Is a complete injury worth treating? People with complete injuries can be evaluated. Goals focus on specific functions, such as sensation, trunk control, spasticity or energy, and are discussed honestly before treatment.

Does the time since injury matter? Yes. Earlier phases have more natural plasticity, but people with chronic injuries can also make gains, especially when treatment is combined with intensive rehabilitation.

Can we combine treatment with our current therapy program? Yes. Most families continue therapy at home and plan a period of more intensive work after treatment.

How to get the most from treatment

1. Record a baseline with your therapists: ISNCSCI exam, SCIM and specific functional tasks.
2. Set two or three concrete goals, such as independent transfers or holding a utensil.
3. Plan intensive rehabilitation in the months after treatment.
4. Protect your general health: skin care, bladder management, nutrition and sleep.
5. Repeat the same measures at three, six and twelve months.

Rehabilitation and standard care

According to NINDS, rehabilitation, prevention of complications and assistive technology are central to SCI care. Activity-based therapy, functional electrical stimulation and, in specialized centers, spinal cord stimulation combined with rehabilitation are part of modern care. Regenerative treatment is added to this foundation.

Preparing for the visit

Bring recent MRI reports, rehabilitation notes with your latest ISNCSCI exam, a medication list and enough catheter and bowel care supplies for the trip plus extra days. Use your pressure-relieving cushion during travel, request airport assistance and travel with a caregiver who knows your routine. Our team arranges wheelchair-accessible transportation and confirms room accessibility in advance.

Who may be a candidate

• Stable SCI, with recent medical records and imaging.
• Stable blood pressure, skin and bladder management.
• No active infection and no cancer within the past five years.
• Participation in rehabilitation before and after treatment.

Questions to ask during your evaluation

• What changes could be realistic for my injury level, AIS grade and time since injury?
• Which measures should my therapists record before treatment?
• Am I a candidate for the intrathecal application?
• How should I plan rehabilitation afterward?

Bottom line

Stem cell therapy for spinal cord injury can be effective as a supportive treatment, with a favorable safety record and improvements in sensory and motor scores in some patients in clinical studies. At Stem Cell Mexico, Wharton's jelly MSCs are given by IV infusion and, in selected cases, intrathecally, alongside rehabilitation, and results vary between patients. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your injury, goals and medical history.